Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-Related Quality of Life (HRQL) Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate (MPA).

Trial Profile

Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-Related Quality of Life (HRQL) Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate (MPA).

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2011

At a glance

  • Drugs Mycophenolate sodium (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Jun 2009 Planned end date changed from 1 Dec 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov record.
    • 03 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top